Immunization against East Coast Fever in field cattle with low infectivity Theileria parva stabilate—preliminary assessment

Abstract

Two Theileria parva sporozoite stabilates stored at −196°C, then at −70°C for six weeks (stabilate 1) and more than six months (stabilate 2) were inoculated into four eight-month old male calves, 1 and 2 (stabilate 1), and 3 and 4 (stabilate 2). Calves 1 and 2 developed pyrexia, enlargement of lymph nodes, and the former died of East Coast Fever. Calves 3 and 4 showed slight enlargement of lymph nodes without fever. Lymph node smears from all calves (from day 10 to 20 post-inoculation) showed lymphoblasts, phagocytic macrophages, and schizonts. Piroplasms were detected in erythrocytes in blood smears from calves 1 and 2 but not in calves 3 and 4. Calves 2, 3 and 4 recovered without any treatment while calf 1 died of East Coast Fever on day 20. Serum samples from recovered calves taken on day 30 of the experiment were positive for antischizont antibodies to T. parva at 1:640 dilution, but pre-inoculation serum samples were negative. Stabilate 2 was used to immunize 64 Boran, Friesian, Ayrshire and crosses with Zebu cattle in four herds with 25% reduction of oxytetracycline dose. All the animals except one calf recovered without any severe reactions. The latter died of disease other than ECF after the monitoring period was over (day 24). Day 30 post-inoculation serum samples were positive for T. parva antischizont antibodies. A follow-up of the remaining animals for over one year revealed no further ECF incidences in these herds. This experiment shows the loss of infectivity of the vaccine stored at temperatures higher than −196°C. dependent on the duration. However, despite the lack of clinical signs in calves 3 and 4, there was cellular response and antibody production, and the stabilate for vaccine against East Coast fever can thus be stored prior to use at higher than −196°C and still maintain capability to produce antibodies in field cattle, eliminating the use of oxytetracycline and monitoring. The vaccine will be cheaper and easier to use and the requirement for liquid nitrogen in the field reduced and the scale of application of the vaccine widened.